Introduction
Cortisol is synthesized from cholesterol in the zona fasciculata of the adrenal cortex in five enzymatic steps: cleavage of the cholesterol side-chain to yield pregnenolone, 3,3-dehydrogenation to progesterone, and successive hydroxylations at the 1 7a, 21, and 11 3 positions by three distinct cytochrome P450 enzymes (P450cl 7, P450c2 1, and P450cl 1). Congenital adrenal hyperplasia, an inherited disorder of cortisol biosynthesis, can result from a defect in any ofthese steps, but in > 90% of cases steroid 2 1-hydroxylase activity is deficient ( 1). The molecular genetic basis of 2 1-hydroxylase deficiency has been extensively studied (reviewed in 2-4).
Classic 1 1/-hydroxylase (P450c I 1) deficiency comprises 5-8% of cases of congenital adrenal hyperplasia, and occurs in about 1/100,000 births in the general Caucasian population (5) . A large number ofcases have been reported in Israel among Jewish immigrants from Morocco, a relatively inbred population (6, 7) . The incidence in this group is currently estimated to be 1/5,000-1/7,000 births, with a gene frequency of 1.2-1.4% (8) .
Patients with this disorder are unable to convert 1 l-deoxycortisol to cortisol. Elevated levels of ACTH cause steroid precursors to accumulate proximal to the blocked step. Many of these precursors are shunted into the pathway for androgen biosynthesis as occurs in 2 1-hydroxylase deficiency. Thus, female patients with this disorder are born with masculinized external genitalia and affected individuals of both sexes undergo rapid somatic growth with premature epiphyseal closure, resulting in short adult stature.
A parallel defect usually exists in the synthesis of 1 7-deoxy steroids, so that deoxycorticosterone is not converted to corticosterone. This pathway is required for aldosterone biosynthesis in the zona glomerulosa, but most of the excessive deoxycorticosterone produced in this disorder originates in the much larger zona fasciculata. Because deoxycorticosterone and some of its metabolites have mineralocorticoid activity, elevated levels may cause hypertension and hypokalemia. About two thirds of untreated patients become hypertensive, sometimes early in life (9) . This clinical feature distinguishes 1 jlp-hydroxylase deficiency from 2 1-hydroxylase deficiency, in which poor aldosterone synthesis causes renal salt wasting in the majority of patients.
The 1 1 -hydroxylase gene, CYP1 1 B 1, is located along with the highly homologous CYP1 1B2 gene on chromosome 8q22 (10, 1 1). Although there are no obviously deleterious mutations (e.g., nonsense mutations or frameshifts) in CYP1 1B2, transcripts are not detectable in Northern blots of normal human adrenal RNA. It is not yet known ifCYP1 1B2 is a pseudogene, which would be reminiscent of the close linkage of the 2 1-hydroxylase gene, CYP2 1, with the CYP21P pseudogene. Alternatively, the product of CYP1 1B2 may be required for aldosterone synthesis (corticosterone methyloxidase II activity) as is the case with the second 11 f3-hydroxylase gene in the rat ( 12) .
Because all 21 -hydroxylase deficiency alleles characterized thus far are the result of recombinations (unequal crossovers or gene conversions) between CYP2 1 and CYP2 I P, it was ofinterest to see if similar mechanisms were responsible for 11hydroxylase deficiency alleles. An Israeli population was examined because of the relatively high frequency of this disorder therein. We found that 1 / 12 mutant alleles contained the same mutation, which was a new point mutation rather than a gene conversion. 
Methods
Patient population. Six families carrying an allele for I l f-hydroxylase deficiency were studied (Table I) ; all were Jews who originated from Morocco. None ofthe families were related, but there was known consanguinity within one family (family C).
Deficiency of l f-hydroxylase activity was suspected on clinical grounds and confirmed on the basis of elevated urinary excretion of tetrahydro-1 -deoxycortisol (the main urinary metabolite of 1 1-deoxycortisol, the immediate precursor for the lf-hydroxylase reaction) and/or plasma 1 I-deoxycortisol levels. Additional biochemical parameters supporting this diagnosis consisted of elevated concentrations of testosterone, androstenedione, and 1-deoxycorticosterone, and suppressed levels of aldosterone and plasma renin activity (6, 7) .
DNA amplification, cloning, and sequence analysis. DNA was prepared from peripheral blood leukocytes from patient A-2, digested with HindIII, phenol-chloroform extracted, and precipitated with ethanol. 1 ,gg of each sample was run in the polymerase chain reaction (13) using reagents supplied by Perkin-Elmer Cetus, Emeryville, CA, and each of three sets ofprimers (200 ng each) in parallel reactions (Table II, Fig. 1 ). These specifically amplified exons 1-2, 3-5, and 6-9 of CYP1 lBl without amplifying CYP1IB2. Specificity of each reaction was tested using cloned CYP1IB and CYP1I B2 genes as control templates. Expected fragment sizes for these three segments were 1.3, 1.7, and 1.8 kb, respectively. Reactions were carried out in a Perkin-Elmer Cetus thermocycler using 35 cycles of940C denaturing for 1 min,65C annealing for 1 min, and 720C extension for 3.5 min, followed by a single 10-min incubation at 72°C. .SEQUENCING The amplified fragments indicated by bars immediately 11 12 below the diagram of the gene were subcloned and sequenced HYBRIDIZATION with universal primers at the ends of each insert and with specific primers indicated by the light arrows. The segment containing exons 8 and 9 that was amplified for allele-specific oligonucleotide hybridization is also shown; the position of the Arg-448 -His mutation is marked by an arrowhead. Numbers above each arrow and below the arrowhead refer to the sequence of each primer listed in Table II. Amplified segments were cloned in pBluescriptKS+ (Stratagene Inc., La Jolla, CA) and supercoiled DNA was sequenced by the chain termination method (14) using modified T7 DNA polymerase (United States Biochemical Corp., Cleveland, OH) (15) and primers corresponding to polylinker sequences and specific internal primers ( Fig. 1) . At least four clones of each amplification reaction were analyzed.
Allele-specific oligonucleotide hybridization (16) . A 0.6-kb fragment containing exons 8 and 9 was amplified from each HindIII-digested sample using primers ( Fig. 1 ) that were demonstrated to be specific for CYP1IBI under the reaction conditions used (the same as above, but with a 3-min extension time). Success of each reaction was confirmed by agarose gel electrophoresis. 300 ng of each amplified sample were dotted on to a nylon membrane (Micron Separation Industries) using a filtration manifold. Membranes were irradiated with 1,200 J of ultraviolet light and hybridized with oligonucleotide probes specific for the Arg448 -. His mutation (see below) and the corresponding normal sequence that were end-labelled with [32p]. Membraneswere washed in 3 M tetramethylammonium chloride for 10 win at 650 and exposed to Kodak XAR film.
Results and Discussion
Arg-448 --His associated with I1f-hydroxylase deficiency. A single mutation in exon 8 of CYP1 lB 1 was identified by sequence analysis of clones from patient A-2. Codon 448, CGC, encoding arginine, was changed to CAC, histidine. This mutation was identified on all four clones of the exons 6-9 region.
Hybridization to dot blots (Fig. 2 ) demonstrated that 11/12 mutant alleles carried the same mutation.
The sulfhydryl of Cys-450 in P450cl 1 is presumed to constitute the fifth ligand to the iron atom of the heme prosthetic group. This residue is completely conserved in all cytochrome P450 enzymes and the surrounding heme binding peptide is also highly conserved (Fig. 3) . In particular, Arg-448 is conserved in all eukaryotic P450 enzymes examined thus far (see references in [17] ) suggesting that substitutions at this position are poorly tolerated. Indeed, mutation of the analogous arginine residue in another P450 enzyme (P450IA2 from rat liver) results in an unstable enzyme (18). Thus, it is reasonable to speculate that the Arg-448 --His mutation interferes with binding or functioning of the heme functional group. Testing of this hypothesis will require expression of normal and mutagenized P450cl 1 in cultured cells, an endeavor that awaits isolation of the full-length cDNA coding sequence. Molecular mechanism generating the mutation. The Arg-448 -. His mutation is a change from CGC to CAC, which is a CpG --TpG mutation on the noncoding strand. This is presumably due to deamination of MCCpG (19) , which is the most frequent type of point mutation in humans (20) . It is notable that this mutation is not normally present in CYP1IB2, and so it cannot have been transferred to CYP 11 B 1 in a gene conversion event. This is in contrast to congenital adrenal hyperplasia due to 2 1-hydroxylase deficiency, for which all mutations described thus far are deletions or gene conversions. Of course, unless it is determined that the product of CYP1IB2 is inactive, it is possible that gene conversions that transfer sequences from CYP1I B2 to CYP1 lBl do not produce 1 l f-hydroxylase deficiency alleles.
Deletions of CYP1 lB 1 have not yet been detected in patients with 1 lf3-hydroxylase deficiency ( [21] , and unpublished observations). Taken together, these findings suggest that intergenic recombination is not as important a mechanism for generating 1 lfl-hydroxylase deficiency alleles as it is for 2 1-hydroxylase deficiency, a hypothesis consistent with the 10-fold lower incidence of 1 I,3-hydroxylase deficiency seen in most populations.
Deficiency ofIlf-hydroxylase in the Israeli population. Because all ofthe families studied here originate from the Moroccan Jewish community, it is likely that the results presented here reflect a founder effect. There was relatively little intermarriage in many relatively small Sephardic (nonEuropean) Jewish communities before emigration to Israel, and so genetic heterogeneity at certain loci may be limited. In a similar example, Israeli patients of Iranian Jewish origin with a defect of aldosterone biosynthesis due to corticosterone methyloxidase II deficiency all had a unique restriction fragment length polymorphism in CYP1 B 1; however, the causative mutation was not identified (20) . Although patients in 5/6 families in this study were presumably genotypically identical, there were significant differences in signs and symptoms of androgen and mineralocorticoid excess, even within families. For example, all affected females were born virilized, but only 5/7 males had an abnormally Highly conserved residues are boxed, and the cysteine that is the fifth ligand to the heme iron is boxed with a double line. large penis in infancy. Only 8/11 patients were hypertensive when untreated and, as has been previously noted (6) , development of hypertension was poorly correlated with blood levels of 11 -deoxycorticosterone. Thus, as is the case with 21 -hydroxylase deficiency, other epigenetic or nongenetic factors probably influence the clinical phenotype of the disorder.
Because a large proportion of 1 lf-hydroxylase deficiency alleles in Israel carry the Arg-448 -* His mutation, prenatal diagnosis of 1 If3-hydroxylase deficiency in this population should be informative in most cases ifthis single mutant allele is screened for. This would provide a useful supplement to the current hormonal methods of prenatal diagnosis (9) . In using this approach for prenatal diagnosis, it will be important to avoid unintentional amplification of CYP1 1 B2, which could lead to a spurious signal with the probe for normal allele, making it difficult to distinguish affected and heterozygous individuals. It is also possible to do carrier screening among Jews of Moroccan ancestry, who comprise -13.5% ofthe current population of Israel (22). This strategy is probably most cost-effective when at least one parent comes from a family known to carry the disease. 
